Table 1. Clinical and laboratory... | American Society of Hematology

Table 1.

Clinical and laboratory characteristics of patients with SCD included in the analysis

Parameters	IQ (n = 5)	Placebo (n = 6)	P value
Age, mean ± SD, y	39.8 ± 13.3	41.3 ± 11.8	.84
Sex (female), n	2	5	NA
BMI, kg/m²	26.0 ± 1.9	26.0 ± 4.9	.99
Genotype (SS)	4∗	6	NA
Clinical events (VOC)	1	1	NA
Therapy, hydroxyurea, n	5	6	NA
Hematological parameters, Hb, (mean ± SD), g/dL	9.9 ± 1.0	9.4 ± 1.6	.59
Absolute reduction compared with BL (mean ± SD)
CI	−0.68 ± 0.94	0.5 ± 0.8	.05†
POHR, (cm²/s)/s	2.3 × 10^–11 ± 8.6 × 10^–10	−4.3 × 10^–10 (7.6 × 10^–10)	.42

Parameters	IQ (n = 5)	Placebo (n = 6)	P value
Age, mean ± SD, y	39.8 ± 13.3	41.3 ± 11.8	.84
Sex (female), n	2	5	NA
BMI, kg/m²	26.0 ± 1.9	26.0 ± 4.9	.99
Genotype (SS)	4∗	6	NA
Clinical events (VOC)	1	1	NA
Therapy, hydroxyurea, n	5	6	NA
Hematological parameters, Hb, (mean ± SD), g/dL	9.9 ± 1.0	9.4 ± 1.6	.59
Absolute reduction compared with BL (mean ± SD)
CI	−0.68 ± 0.94	0.5 ± 0.8	.05†
POHR, (cm²/s)/s	2.3 × 10^–11 ± 8.6 × 10^–10	−4.3 × 10^–10 (7.6 × 10^–10)	.42

BMI, body mass index; Hb, hemoglobin; NA, not applicable; SD, standard deviation; SS, sickle cell anemia.

One participant had HbSβ⁺-thalassemia.

Unpaired t test comparing the absolute reduction in CI between the groups.